The links after "Participants" show which Southwest Oncology Group institutions are eligible to participate in this study.

The orange "Where is this Study Open?" tab at the bottom of the page shows the institutions whose Institutional Review Boards (IRBs) have approved the protocol so that it can be opened at that institution. Clicking on the Institution Name will show the points of contact for information about this study at that institution.

Status Notes: Effective 10/15/09 this study will be permanently closed to accrual.

Disease Committee: Genitourinary Cancer

Participants: Members, CCOP, Affiliates, UCOP, Medical Oncologists, Surgeons, Pathologists

Eligibility Criteria: Pts must have histologically proven, recurrent superficial TCC of the bladder Stage T1 Grade 2-4; Stage Tis; Stage Ta Grade 3-4; or multifocal (>2 lesions) Stage Ta any Grade. Must have rec'd at least 2 previous courses of intravesical BCG up to 3 yrs prior to reg. May have rec'd 1 course of chemo. Must not have rec'd gemcitabine prior to reg. Must have had a TURBT or bladder bx documenting above stage & grade at least 6 wks after last BCG and/or immunotherapy or at least 14 days after previous intravesical chemo and w/in 60 days prior to reg. All visible tumor must have been resected at last bx. Must have available representative slides for central path review. Must have had a negative upper tract imaging study w/in 2 yrs of reg w/no evidence of urethral or renal pelvis TCC. Must not have rec'd any prior pelvic RT nor planning to receive any concurrent RT. Must be offered opportunity to consent for specimen submission per Section 15. Must have Zubrod PS 0-2.